Question to the Department of Health and Social Care:

To ask the Secretary of State for Health, what estimate he has made of how many relapsed/refractory Hodgkin lymphoma patients will not receive stem cell transplants if brentuximab vedotin is removed as a standard of care.

The Department has made no such estimate. The National Institute for Health and Care Excellence (NICE) is currently appraising brentuximab for treating CD30+ Hodgkin lymphoma and recently consulted on its draft guidance. NICE has not yet published final guidance. Brentuximab is currently available to National Health Service patients with relapsed and refractory Hodgkin lymphoma through the Cancer Drugs Fund.